1 November 2016 15:30 Transaction by Person Closely Associated with a Person Discharging Managerial Responsibilities Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation On 31 October 2016, Mrs Susan Chipchase notified us that, on 27 October 2016, she purchased 100 AstraZeneca PLC Ordinary Shares of US$0.25 each at a price of £48.08 per share. Mrs Chipchase is a person closely associated with Graham Chipchase, a Non -Executive Director of AstraZeneca PLC. The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them +--+----------------------------------------+-------------+---------+ |1 |Details of the person discharging | | |managerial responsibilities / person | | |closely associated | +--+----------------------------------------+-------------+---------+ |a)|Name |Susan Chipchase | +--+----------------------------------------+-------------+---------+ |2 |Reason for the notification | +--+----------------------------------------+-------------+---------+ |a)|Position/status |Person Closely | | | |Associated with | | | |a Person | | | |Discharging | | | |Managerial | | | |Responsibilities | | | |(PDMR) in | | | |respect of | | | |AstraZeneca PLC | +--+----------------------------------------+-------------+---------+ |b)|Initial notification /Amendment |Initial | | | |notification | +--+----------------------------------------+-------------+---------+ |3 |Details of the issuer, emission | | |allowance market participant, auction | | |platform, auctioneer or auction | | |monitor | +--+----------------------------------------+-------------+---------+ |a)|Name |AstraZeneca PLC | +--+----------------------------------------+-------------+---------+ |b)|LEI |Not applicable | +--+----------------------------------------+-------------+---------+ |4 |Details of the transaction(s): section | | |to be repeated for (i) each type of | | |instrument; (ii) each type of | | |transaction; (iii) each date; and (iv) | | |each place where transactions have | | |been conducted | +--+----------------------------------------+-------------+---------+ |a)|Description of the financial instrument,|Ordinary Shares | | |type of instrumentIdentification code |of US$0.25 each | | | |in AstraZeneca | | | |PLCGB0009895292 | +--+----------------------------------------+-------------+---------+ |b)|Nature of the transaction |Acquisition | +--+----------------------------------------+-------------+---------+ |c)|Price(s) and volume(s) |Price(s) |Volume(s)| +--+----------------------------------------+-------------+---------+ | | |4807.95 pence|100 | +--+----------------------------------------+-------------+---------+ |d)|Aggregated information- Aggregated |Not applicable - | | |volume- Price |single | | | |transaction | +--+----------------------------------------+-------------+---------+ |e)|Date of the transaction |27 October 2016 | +--+----------------------------------------+-------------+---------+ |f)|Place of the transaction |London | +--+----------------------------------------+-------------+---------+ About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. Media Enquiries Neil Burrows UK/Global +44 203 749 5637 Vanessa Rhodes UK/Global +44 203 749 5736 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Henry Wheeler Oncology +44 203 749 5797 Mitchell Chan Oncology +1 240 477 3771 Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970 Nick Stone Respiratory +44 203 749 5716 Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711 US toll free +1 866 381 7277 Adrian Kemp Company Secretary, AstraZeneca PLC -ENDS-
Dealing by Person Closely Associated
| Quelle: AstraZeneca PLC
Anhänge
